{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Robetorye RS"],"funding":["Division of Cancer Epidemiology and Genetics, National Cancer Institute","Center for Individualized Medicine, Mayo Clinic","NCI NIH HHS"],"pagination":["3-10"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8386504"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["Diffuse large B-cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including Germinal Center B-cell type, Activated B-cell type, and Unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed pros"],"journal":["Journal of hematopathology"],"pubmed_title":["Incorporation of Digital Gene Expression Profiling for Cell-of-Origin Determination (Lymph2Cx Testing) into the Routine Work-Up of Diffuse Large B-Cell Lymphoma."],"pmcid":["PMC8386504"],"funding_grant_id":["N/A","U01CA57581","U01 CA157581"],"pubmed_authors":["Rimsza LM","Ramsower CA","Glinsmann-Gibson BJ","Rosenthal AC","Robetorye RS","Wendel Spiczka AJ","Yip TK"],"additional_accession":[]},"is_claimable":false,"name":"Incorporation of Digital Gene Expression Profiling for Cell-of-Origin Determination (Lymph2Cx Testing) into the Routine Work-Up of Diffuse Large B-Cell Lymphoma.","description":"Diffuse large B-cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including Germinal Center B-cell type, Activated B-cell type, and Unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed pros","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2025-04-20T00:32:12.807Z","creation":"2022-02-11T09:50:06.009Z"},"accession":"S-EPMC8386504","cross_references":{"pubmed":["34447482"],"doi":["10.1007/s12308-019-00344-0"]}}